Clinical trial · Observational
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (PAVE)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Jakavi® therapy for polycythemia vera (PV) has so far been studied exclusively in clinical trials and at selected clinical trial centres. This observational study is intended to document the therapy of PV in daily practice with a broad patient population and a geographically representative selection of German centres (both hospitals and practices). The prospective mapping of daily practice reality is thus the main goal of this project.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Jakavi | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- JAK inhibitor naive
- description
- JAK inhibitor naive patients
- interventionNames
- Other: Jakavi
- label
- JAK inhibitor pre-treated
- description
- JAK inhibitor pre-treated patients (Jakavi® or any other JAK inhibitor for ≥3 months)
- interventionNames
- Other: Jakavi
Primary outcomes (8)
- measure
- Dosing
- timeFrame
- Up to 36 months
- description
- Number of patients by initial dosing and number of patients with dose modifications will be provided
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
Inclusion Criteria: * Adult male and female patients with PV for whom Jakavi® therapy is indicated according to the European summary of product characteristics * Patients who have been informed about this NIS and gave written consent
References
Publications (0)
Data not yet available